Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid

American Journal of Obstetrics and Gynecology

Volumn 215, Issue 4, 2016, Pages 497.e1-497.e7

  Fokina, Valentina M ^a   West, Holly ^a   Oncken, Cheryl ^b   Clark, Shannon M ^a   Ahmed, Mahmoud S ^a   Hankins, Gary D V ^a   Nanovskaya, Tatiana N ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

amniotic fluid; bupropion; hydroxybupropion; placental passage; pregnancy; threohydrobupropion; umbilical cord plasma

Indexed keywords

AMFEBUTAMONE; DRUG METABOLITE; RADAFAXINE; THREOHYDROBUPROPION; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; HYDROBUPROPION;

ADULT; AMNION FLUID; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DEPRESSION; DRUG BLOOD LEVEL; FEMALE; FETUS CIRCULATION; GESTATIONAL AGE; HUMAN; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATERNAL BLOOD; MATERNAL PLASMA; MEDICAL EXAMINATION; MEDICAL HISTORY; PLACENTA; PLACENTAL TRANSFER; PREGNANCY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SMOKING CESSATION; UMBILICAL CORD BLOOD; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; COMPLICATION; DRUG EFFECTS; FETOMATERNAL TRANSFUSION; FETUS; FETUS BLOOD; METABOLISM; PREGNANCY COMPLICATIONS; PSYCHOLOGY;

ADULT; AMNIOTIC FLUID; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DEPRESSION; FEMALE; FETAL BLOOD; FETUS; HUMANS; MATERNAL-FETAL EXCHANGE; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS; SMOKING CESSATION;

EID: 84979649262     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2016.05.016     Document Type: Article

References (30)

1. 1 Way, C.M., Safety of newer antidepressants in pregnancy. Pharmacotherapy 27 (2007), 546–552.
2. 2 Patkar, A.A., Bilal, L., Masand, P.S., Pharmacotherapy of depression in pregnancy. Ann Clin Psychiatry 16 (2004), 87–100.
3. 3 Gentile, S., The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 28 (2005), 137–152.
4. 4 Wellbutrin SR [product monograph]. Brentford, United Kingdom: GlaxoSmithKline; 2014.
5. 5 Wellbutrin XL [product monograph]. Bridgewater, NJ: Valeant Pharmaceuticals International; 2014.
6. 6 Curtin, S.C., Matthews, T.J., Smoking Prevalence and Cessation Before and During Pregnancy: Data From the Birth Certificate, 2014. Natl Vital Stat Rep 65 (2016), 1–14.
7. 7 Zyban [product monograph]. Brentford, United Kingdom: GlaxoSmithKline; 2014.
8. 8 Arias, H.R., Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions?. Int J Biochem Cell Biol 41 (2009), 2098–2108.
9. 9 Jefferson, J.W., Pradko, J.F., Muir, K.T., Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 27 (2005), 1685–1695.
10. 10 Golden, R.N., De Vane, C.L., Laizure, S.C., Rudorfer, M.V., Sherer, M.A., Potter, W.Z., Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 45 (1988), 145–149.
11. 11 Martin, P., Massol, J., Colin, J.N., Lacomblez, L., Puech, A.J., Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 23 (1990), 187–194.
12. 12 Bondarev, M.L., Bondareva, T.S., Young, R., Glennon, R.A., Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol 474 (2003), 85–93.
13. 13 Earhart, A.D., Patrikeeva, S., Wang, X., et al. Transplacental transfer and metabolism of bupropion. J Matern Fetal Neonatal Med 23 (2010), 409–416.
14. 14 Hemauer, S.J., Patrikeeva, S.L., Wang, X., et al. Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol 80 (2010), 1080–1086.
15. 15 Wang, X., Abdelrahman, D.R., Zharikova, O.L., et al. Bupropion metabolism by human placenta. Biochem Pharmacol 79 (2010), 1684–1690.
16. 16 Loughhead, A.M., Stowe, Z.N., Newport, D.J., Ritchie, J.C., DeVane, C.L., Owens, M.J., Placental passage of tricyclic antidepressants. Biol Psychiatry 59 (2006), 287–290.
17. 17 Underwood, M.A., Gilbert, W.M., Sherman, M.P., Amniotic fluid: not just fetal urine anymore. J Perinatol 25 (2005), 341–348.
18. 18 Wang, X., Vernikovskaya, D.I., Abdelrahman, D.R., Hankins, G.D., Ahmed, M.S., Nanovskaya, T.N., Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 70 (2012), 320–329.
19. 19 Fava, M., Rush, A.J., Thase, M.E., et al. 15 Years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 7 (2005), 106–113.
20. 20 Yonkers, K.A., Wisner, K.L., Stewart, D.E., et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 31 (2009), 403–413.
21. 21 Benowitz, N.L., Zhu, A.Z., Tyndale, R.F., Dempsey, D., Jacob, P. III, Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics 23 (2013), 135–141.
22. 22 Molnari, J.C., Myers, A.L., Carbonyl reduction of bupropion in human liver. Xenobiotica 42 (2012), 550–561.
23. 23 Zhu, A.Z., Zhou, Q., Cox, L.S., Ahluwalia, J.S., Benowitz, N.L., Tyndale, R.F., Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. Drug Metab Dispos 42 (2014), 1971–1977.
24. 24 Yasuda, S.U., Zhang, L., Huang, S.M., The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 84 (2008), 417–423.
25. 25 Anderson, D.F., Phernetton, T.M., Rankin, J.H., Prediction of fetal drug concentrations. Am J Obstet Gynecol 137 (1980), 735–738.
26. 26 Beall, M.H., van den Wijngaard, J.P., van Gemert, M.J., Ross, M.G., Amniotic fluid water dynamics. Placenta 28 (2007), 816–823.
27. 27 Ring, J.A., Ghabrial, H., Ching, M.S., Smallwood, R.A., Morgan, D.J., Fetal hepatic drug elimination. Pharmacol Ther 84 (1999), 429–445.
28. 28 Croom, E.L., Stevens, J.C., Hines, R.N., Wallace, A.D., Hodgson, E., Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem Pharmacol 78 (2009), 184–190.
29. 29 Gupta, S., Alfaidy, N., Holloway, A.C., et al. Effects of cortisol and estradiol on hepatic 11beta-hydroxysteroid dehydrogenase type 1 and glucocorticoid receptor proteins in late-gestation sheep fetus. J Endocrinol 176 (2003), 175–184.
30. 30 Tong, X.L., Wang, L., Gao, T.B., Qin, Y.G., Qi, Y.Q., Xu, Y.P., Potential function of amniotic fluid in fetal development–novel insights by comparing the composition of human amniotic fluid with umbilical cord and maternal serum at mid and late gestation. J Chin Med Assoc 72 (2009), 368–373.